维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="Nikrad"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	The proteasome inhibitor bortezomib sensitizes ceils to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim 显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1
2	The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3 - only proteins Bik andBIM显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1
3	The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim显示文摘	NIKRAD M JOHNSON T PUTHALALATH H	2005	Mol Cancer Ther2005，4，3：	1
4	The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3 - only proteins Bik and Bim 显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1
5	The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1
6	The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and easpase 9-negative or Bcl-xL overexpressing cells 显示文摘	Johnson TR Stone K Nikrad M	2003	Oncogene2003，22，32：	1
7	The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and casepase 9-negative or Bcl-xL overexp ressing cells显示文摘	Johnson T R Stone K Nikrad M		0，，32：	1
8	The protea- some inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1
9	The proteasome in- hibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim 显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1
10	The proteasome inhibi- tor bortezomib sensitizes cells to kilhng by death receptor ligand TRAIL via BH3-only proteins bik and bim显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1
11	The proteasome in- hibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim 显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，，4：	1
12	The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells 显示文摘	Johnson TR Stone K Nikrad M	2003	Oncogene2003，22，32：	1
13	The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing ceils 显示文摘	JOHNSON T R STONE K NIKRAD M	2003	Oncogene2003，22，32：	1
14	Catalytic reduction of nitroarenes with hydroazine hydrate in suitable solvents显示文摘	Ayyanger N R Lugade A G Nikrad P V	1981	Synthesis1981，，：	1
15	Innate immune response to influenza A virus in differentiated human alveolar type ]I cells 显示文摘	Wang JR Nikrad MP Phang T	2011	Am J Respir Cell Mol Biol2011，45，3：	1
16	Innate immune responseof human alveolar macrophages during influenza A infection 显示文摘	Wang J Nikrad MP Travanty EA	2012	PLoS One2012，7，29：	1
17	The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim 显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1
18	Distal esophageal spasm:Update on diagnosis and management in the era of high-resolution manometry显示文摘Distal esophageal spasm(DES)is a rare major motility disorder in the Chicago classification of esophageal motility disorders(CC).DES is diagnosed by finding of≥20%premature contractions,with normal lower esophageal sphincter(LES)relaxation on high-resolution manometry(HRM)in the latest version of CCv3.0.This feature differentiates it from achalasia type 3,which has an elevated LES relaxation pressure.Like other spastic esophageal disorders,DES has been linked to conditions such as gastroesophageal reflux disease,psychiatric conditions,and narcotic use.In addition to HRM,ancillary tests such as endoscopy and barium esophagram can provide supplemental information to differentiate DES from other conditions.Functional lumen imaging probe(FLIP),a new cutting-edge diagnostic tool,is able to recognize abnormal LES dysfunction that can be missed by HRM and can further guide LES targeted treatment when esophagogastric junction outflow obstruction is diagnosed on FLIP.Medical treatment in DES mostly targets symptomatic relief and often fails.Botulinum toxin injection during endoscopy may provide a temporary therapy that wears off over time.Myotomy through peroral endoscopic myotomy or via surgical Heller myotomy can provide long term relief in cases with persistent symptoms.	Harika Gorti Salih Samo Nikrad Shahnavaz Emad Qayed	2020	World Journal of Clinical Cases2020，8，6：	1
19	Innate immune responseof human alveolar macrophages during influenza A infection 显示文摘	Wang J Nikrad MP Travanty EA	2012	PLoS One2012，7，29：	1
20	The proteasome inhibitor bortezomib sensitizes cells to killing hy death receptor ligand TRAIL via BH3-only proteins Bik and Bim显示文摘	Nikrad M Johnson T Puthalalath H	2005	Mol Cancer Ther2005，4，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示